Pharmaceutical

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing…

1 year ago

IntegriChain Revenue Optimization Experts to Speak at Informa’s Pharma/BioTech GTN Summit

PHILADELPHIA, Nov. 11, 2024 /PRNewswire/ -- IntegriChain, the leading provider of pharma revenue optimization technology and insights for the pharmaceutical…

1 year ago

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients…

1 year ago

GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology™

Collaboration will leverage GE HealthCare’s legacy and scale of imaging innovation and RadNet’s DeepHealth AI-powered clinical and workflow solutions to…

1 year ago

CardioComm Solutions Integrates ECG Technology into Sony’s mSafety Platform

Collaboration Brings Advanced ECG Monitoring to Sony's Wearable Health SolutionToronto, Ontario--(Newsfile Corp. - November 11, 2024) - CardioComm Solutions, (TSXV:…

1 year ago

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

Click here to register for investor webcastCompany plans to file its Earnings Report on November 13, 2024 on Form 10-Q…

1 year ago

Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated…

1 year ago

Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with evidence of…

1 year ago

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company…

1 year ago